[Survival of patients with zidovudine resistant HIV].
The survival of 35 patients with AIDS or advanced HIV infection on zidovudine treatment was related to the viral sensitivity to the drug and to the CD4+ cell count. Fourteen patients died, the survivors were followed up for an average of 804 days. In a univariate Cox model, survival was strongly related to log IC90 (p = 0.0003) and to the CD4+ count (p = 0.0002). In a bivariate model, log IC90 and the CD4+ count contributed to the prediction of survival (p = 0.12 and 0.06, respectively). Large studies of combination or alternation therapy with several anti-HIV-drugs should be given high priority.
Gøtzsche
P C
PC
Epidemiafdeling M, Rigshospitalet, København.
Nielsen
C
C
Gerstoft
J
J
Nielsen
C M
CM
Vestergaard
B F
BF
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology / Q000401:mortality*; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D015331:Cohort Studies; D004311:Double-Blind Method; D004352:Drug Resistance, Microbial; D006679:HIV Seropositivity / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D011379:Prognosis; D015215:Zidovudine / Q000627:therapeutic use*
D015215:Zidovudine
Patientoverlevelse ved zidovudinresistent HIV.